{
  "docId": "019dd923-622b-71dc-a6d9-a17d7f297d05",
  "docSlug": "f72bb77d31b3",
  "documentTitle": "Alexion Pharmaceuticals, Inc. (ALXN)",
  "authorId": "02_Elliott_Management",
  "authorName": "Elliott",
  "documentKindSlug": "shareholder-letter",
  "documentKindLabel": "Shareholder letter",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2020-05-12 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.7072243,
  "pageNumber": 2,
  "pageCount": 10,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "peer_gap",
  "function": "expose_gap",
  "density": "dense",
  "nDataPoints": 36,
  "notes": "The slide uses a combination of a line chart for valuation erosion and bar charts for relative performance benchmarking.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "line_chart",
    "bar_chart_grouped",
    "bar_chart_vertical",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-a17d7f297d05/2",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-a17d7f297d05#slide-2",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Indeed, during your tenure, Alexion is the worst performer across the broader large-cap biopharma sector.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b9-a1bdd21470f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.09,
        "y": 0.41
      },
      "kind": "chart",
      "text": "Cumulative Relative Total Shareholder Returns (%)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98931e57-d7d8-4f9f-a834-7822b4c8c9a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.09,
        "y": 0.61
      },
      "kind": "chart",
      "text": "Total Shareholder Return over ALXN Chairman Tenure (%)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9af3e18-4966-4b75-aa6a-c99df9a18bbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.09,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Alexion EV / EBITDA",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7b2bed4-9452-4623-9752-05959a3addf6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Total Shareholder Return: (20)%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b9-a570d7d5fbd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.09,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Despite Alexion's attractive franchise and favorable operating performance, the Company's share price has persistently struggled over the last few years.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8cc4099-8773-4c14-8583-44579f28c4e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.82,
        "x": 0.09,
        "y": 0.81
      },
      "kind": "source-note",
      "text": "Based on Bloomberg EV / FY1 EBITDA as of 8-May-2020...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "226cc9f2-d92c-492c-9ac4-f71cf941538c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.09,
        "y": 0.08
      },
      "kind": "title",
      "text": "Alexion Has Been a Persistent Underperformer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61ff07f3-727c-4da8-baa4-4150a3135cb8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "9a7442e8-a173-45b0-8f36-16ea672c7a28",
      "evidence": "chart/bar-vertical: Total Shareholder Return over ALXN Chairman Tenure (%)",
      "confidence": 0.5
    },
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "4cde9d19-cbd4-462a-a4e4-0498e5582fa0",
      "evidence": "Indeed, during your tenure, Alexion is the worst performer across the broader large-cap biopharma sector.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "9d8a8a8b-6431-4b4e-9068-762968b967bb",
      "evidence": "Comparing Alexion's performance against peers and indices to highlight underperformance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "83dc7e47-222b-452a-8892-5d402c1dd0e4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 2-3 identify the problem of underperformance",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}